Federated Hermes Inc. Has $5.75 Million Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Federated Hermes Inc. lifted its position in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 43.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,237,505 shares of the biopharmaceutical company’s stock after buying an additional 672,803 shares during the quarter. Federated Hermes Inc. owned about 2.14% of Revance Therapeutics worth $5,750,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of RVNC. Certuity LLC acquired a new position in Revance Therapeutics in the 2nd quarter valued at $26,000. Nisa Investment Advisors LLC grew its position in shares of Revance Therapeutics by 2,167.5% in the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 18,077 shares during the last quarter. Clarity Capital Partners LLC bought a new position in shares of Revance Therapeutics in the first quarter worth about $59,000. Arizona State Retirement System lifted its position in shares of Revance Therapeutics by 27.6% during the 2nd quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 5,996 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Revance Therapeutics by 67.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 16,981 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 6,826 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. William Blair reiterated a “market perform” rating on shares of Revance Therapeutics in a report on Monday, August 12th. HC Wainwright cut shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 13th. Barclays restated an “equal weight” rating and issued a $7.00 price target (down from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. Guggenheim reaffirmed a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Finally, Stifel Nicolaus decreased their target price on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Ten research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.50.

Revance Therapeutics Trading Up 0.4 %

NASDAQ RVNC opened at $5.99 on Thursday. Revance Therapeutics, Inc. has a 1-year low of $2.30 and a 1-year high of $14.24. The company has a market capitalization of $625.65 million, a price-to-earnings ratio of -1.65 and a beta of 1.00. The stock’s 50 day moving average is $5.24 and its two-hundred day moving average is $4.29.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.12. The company had revenue of $65.39 million during the quarter, compared to analyst estimates of $66.30 million. Revance Therapeutics’s quarterly revenue was up 20.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.80) EPS.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.